sellWeak
Emil Kuriakose sold $50k of TERN
Chief Medical Officer at Terns Pharmaceuticals, Inc.. 942 shares at an average of $52.75, traded Apr 1, 2026, filed Apr 2, 2026.
Warning score
22Value
$50k
942 shares
Holdings after
105,673
-1% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleOfficer
- +7Trade size$50k at market
- 0Share of holdings soldSold 0.9% of holdings
- 0ClusterNo other insider selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001892413-26-000006, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Apr 1, 2026 | SOpen-market sale Common Stock | -942 | $52.75 | $50k | 105,673 | Apr 2, 2026 |
Related signals
Other insiders at Terns Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 11Weak | Terns Pharmaceuticals, Inc. | Amy L. Burroughs Chief Executive Officer | $681k 14,583 shares | -5% | |
| 9Weak | Terns Pharmaceuticals, Inc. | Amy L. Burroughs Chief Executive Officer | $572k 14,583 shares | -5% | |
| 28Weak | Terns Pharmaceuticals, Inc. | Amy L. Burroughs Chief Executive Officer | $2.5M 68,749 shares | -19% | |
| 53Moderate | Terns Pharmaceuticals, Inc. | Amy L. Burroughs Chief Executive Officer | $2.7M 71,339 shares | -34% | |
| 29Weak | Terns Pharmaceuticals, Inc. | Emil Kuriakose Chief Medical Officer | $45k 1,155 shares | -2% | |
| 17Weak | Terns Pharmaceuticals, Inc. | Jill M. Quigley Sr. Advisor & Strategy Officer | $441k 24,520 shares | -100% | |
| 15Weak | TERNsell Terns Pharmaceuticals, Inc. | Emil Kuriakose Chief Medical Officer | $7,407 944 shares | -2% | |
| 15Weak | TERNsell Terns Pharmaceuticals, Inc. | Emil Kuriakose Chief Medical Officer | $3,640 853 shares | -2% | |
| 51Moderate | Terns Pharmaceuticals, Inc. | Andrew Gengos Chief Financial Officer | $39k 10,000 shares | +67% | |
| 52Moderate | Terns Pharmaceuticals, Inc. | Amy L. Burroughs Chief Executive Officer | $90k 23,314 shares | +98% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.